Literature DB >> 15029874

Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy.

K Wickström1, G Edelstam, C H Löwbeer, L O Hansson, A Siegbahn.   

Abstract

During pregnancy, significant changes occur in the hemostatic system and in the plasma levels for several plasma proteins, especially towards term. In this study changes occurring during normal pregnancy and immediately postpartum were investigated to establish adequate reference intervals for important hemostatic parameters. Blood samples were collected during pregnancy weeks 33, 36, 39 and 1-3 h after delivery from 153 healthy pregnant women with at least one previous normal pregnancy. The plasma samples were analyzed for antithrombin, von Willebrand factor (vWf), free protein S and fibronectin. Fibronectin and vWf are contact-promoting proteins responsible for adhesion and aggregation during primary hemostasis, but are also released from thrombocytes during activation of the coagulation process. Antithrombin is the most important primary physiological inhibitor of activated serine proteases related to the coagulation cascade. Protein S is a co-factor to protein C and in cooperation is also an important inhibitor of the coagulation cascade. During third-trimester pregnancy, vWf was higher than in non-pregnant women, and continued to increase postpartum. The fibronectin plasma level was mostly unchanged in comparison with non-pregnant values. Within this reference interval it gradually increased during the third trimester, but fell slightly postpartum. Antithrombin decreased slightly during the third trimester and even further, postpartum. Free protein S decreased markedly but to a stable level from week 33 to 39, decreasing even more postpartum. The present results are concordant with clinical knowledge of increased risk of thrombosis during pregnancy and early puerperium, with increased levels of vWf and fibronectin and decreased levels of antithrombin and free protein S. Clearly, current reference values based on healthy non-pregnant subjects are not usable during late pregnancy and immediately postpartum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029874     DOI: 10.1080/00365510410003859

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  Antithrombin deficiency in pregnancy.

Authors:  Shivani Durai; Lay Kok Tan; Serene Lim
Journal:  BMJ Case Rep       Date:  2016-05-20

2.  Natural coagulation inhibitors and active protein c resistance in preeclampsia.

Authors:  Cengiz Demir; Imdat Dilek
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

3.  Alterations of fibrin network structure mediated by dermatan sulfate.

Authors:  Ana María Lauricella; María Mercedes Castañon; Lucía C Kordich; Irene L Quintana
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

4.  The association between ABO blood group and obstetric hemorrhage.

Authors:  Lior Drukker; Naama Srebnik; Deborah Elstein; Lorinne Levitt; Arnon Samueloff; Rivka Farkash; Sorina Grisaru-Granovsky; Hen Y Sela
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

Review 5.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  New trimester-specific reference intervals for clinical biochemical tests in Taiwanese pregnant women-cohort of TMICS.

Authors:  Hui-Ming Chen; Fu-Chen Kuo; Chou-Cheng Chen; Chia-Fang Wu; Chien-Wen Sun; Mei-Lien Chen; Chia-Jung Hsieh; Shu-Li Wang; Ming-Tsang Wu
Journal:  PLoS One       Date:  2020-12-14       Impact factor: 3.240

7.  Reference intervals for coagulation parameters in non-pregnant and pregnant women.

Authors:  Mengyu Fu; Junjie Liu; Jinfang Xing; Yanpeng Dai; Yanzi Ding; Kainan Dong; Xuewei Zhang; Enwu Yuan
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.996

8.  Plasma Antithrombin Activity during Long-Term Magnesium Sulfate Administration for Preeclampsia without Severe Hypertension.

Authors:  Kaori Moriuchi; Kaoru Kawasaki; Maako Hayashi; Akihiko Ueda; Yukio Yamanishi; Haruta Mogami; Kohei Fujita; Reona Shiro; Yoshie Yo; Masaki Mandai; Noriomi Matsumura
Journal:  Healthcare (Basel)       Date:  2022-08-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.